Company / Current Assets
Inmune Bio, Inc. Current Assets History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$29.9M
FY2025
5-year range
$22.7M / $82.6M
FY2021-FY2025
Trend
+31.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets returned to growth in FY2025 after 3 years of decline, reaching $30M.
Based on SEC 10-K filings.
$30M in FY2025 with a 5-year CAGR of +4.5%.
Declined from $40M to $30M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -22.7%
- 5-Year CAGR
- +4.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +4.5%, indicating consistent growth.
- In FY2025, current assets increased 31.9% year-over-year.
- Peak current assets was recorded in FY2021.
- Lowest current assets in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $29.9M | +31.9% |
| FY2024 | $22.7M | -43.3% |
| FY2023 | $39.9M | -38.2% |
| FY2022 | $64.7M | -21.7% |
| FY2021 | $82.6M | +244.4% |
| FY2020 | $24.0M | +2724.0% |
| FY2018 | $849.3K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026